Logo

GrowLab Reports Results of Comacadine for the Treatment of Diabetes Mellitus

Share this
GrowLab Reports Results of Comacadine for the Treatment of Diabetes Mellitus

GrowLab Reports Results of Comacadine for the Treatment of Diabetes Mellitus

Shots:

  • The company evaluated Comacadine in a clinical trial for 7mos. on patients (n=25) with diabetes mellitus who were on either insulin or metformin/glibenclamide treatment for 2 to 2.5yrs.
  • The results of the trial demonstrated 96% clinical remission in diabetes with no side effects, while 2 patients with high cholesterol experienced a decrease in their cholesterol levels when treated with Comacadine on which the company plans to initiate a clinical study
  • GrowLab will initiate an M&A transaction with NASDAQ listed SPAC or other multinational pharmaceutical companies for the commercial production of Comacadine to treat Diabetes, Glaucoma & Arthritis along with Grolatine to treat chronic pain, sickle cell disease & prostate cancer

Ref: PRNewswire | Image: GrowLab

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions